Trial · NCT05041257
Adverse events73
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 73
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Mirvetuximab Soravtansine | 7 | 79 | 11 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Mirvetuximab Soravtansine | 11 | 79 | 34 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Mirvetuximab Soravtansine | 5 | 79 | 9 |
| other | CATARACT | Eye disorders | Mirvetuximab Soravtansine | 27 | 79 | 41 |
| other | CORNEAL EPITHELIAL MICROCYSTS | Eye disorders | Mirvetuximab Soravtansine | 5 | 79 | 11 |
| other | DRY EYE | Eye disorders | Mirvetuximab Soravtansine | 32 | 79 | 49 |
| other | EYE PAIN | Eye disorders | Mirvetuximab Soravtansine | 5 | 79 | 9 |
| other | KERATITIS | Eye disorders | Mirvetuximab Soravtansine | 6 | 79 | 12 |
| other | KERATOPATHY | Eye disorders | Mirvetuximab Soravtansine | 26 | 79 | 57 |
| other | PHOTOPHOBIA | Eye disorders | Mirvetuximab Soravtansine | 13 | 79 | 19 |
| other | VISION BLURRED | Eye disorders | Mirvetuximab Soravtansine | 52 | 79 | 116 |
| other | VISUAL ACUITY REDUCED | Eye disorders | Mirvetuximab Soravtansine | 7 | 79 | 9 |
| other | VITREOUS FLOATERS | Eye disorders | Mirvetuximab Soravtansine | 6 | 79 | 6 |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Mirvetuximab Soravtansine | 6 | 79 | 6 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Mirvetuximab Soravtansine | 14 | 79 | 18 |
| other | CONSTIPATION | Gastrointestinal disorders | Mirvetuximab Soravtansine | 14 | 79 | 17 |
| other | DIARRHOEA | Gastrointestinal disorders | Mirvetuximab Soravtansine | 24 | 79 | 46 |
| other | FLATULENCE | Gastrointestinal disorders | Mirvetuximab Soravtansine | 4 | 79 | 5 |
| other | NAUSEA | Gastrointestinal disorders | Mirvetuximab Soravtansine | 29 | 79 | 42 |
| other | STOMATITIS | Gastrointestinal disorders | Mirvetuximab Soravtansine | 5 | 79 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05041257/events